Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis

New findings from an observational study have elucidated physician treatment choices for patients with psoriatic arthritis (PsA) and demonstrated comparable real-world efficacy between guselkumab and IL-17 inhibitor (IL-17i) treatments.

These findings, from the PsABIOnd study, were presented by Laure Gossec, MD, PhD, Professor of Rheumatology, Pitié-Salpêtrière Hospital and Sorbonne University - Pierre et Marie Curie Campus, Paris, France, at the American College of Rheumatology (ACR) Convergence 2024, held November 14-19 in Washington, DC.

“We now have many drugs available for the treatment of PsA. We have 6 different modes of action now available to us on top of conventional synthetic DMARDs, and we have data from randomized control trials showing that each of these drugs works better than placebo, but we are lacking large comparative, head to head trials of 1 drug against another, in particular for modes of action which have appeared after the TNF inhibitors,” Gossec told HCPLive® during the meeting.

Gossec and colleagues found that treatment persistence was high at 6 months, with 94.2% of the guselkumab group and 93.3% of the IL-17i group remaining on initial treatments at 6 months. Similar rates of efficacy were seen at 6 months, with 39.7% of the guselkumab group and 34.3% of the IL-17i group achieving cDAPSA LDA/REM.

In this clip, Gossec went over the findings from PsABIOnd, the importance of the study, and characteristics of the guselkumab group compared with the IL-17i group. She also discussed continuing research on treatment choices for PsA.

“We really need to insist on the importance of shared decision making in PSA, because it's a disease where the patient burden is really high, not only because of the disease itself, the skin involvement, but also the comorbidities. And we really need to make the best choice for our patients,” Gossec said.

Relevant disclosures for Gossec include AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Sandoz, and UCB.

REFERENCE

Gossec L, Sharaf M, Baraliakos X, et al. Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study. Presented at: ACR Convergence 2024; November 14-19; Washington, DC. Abstract 1464